.png){kind=icon}
You have identified the target and created some potential leads/candidates, and now you need a trusted partner to help you take the next step towards understanding if your molecule is efficacious..
With our depth of knowledge in pharmacology and customized disease models, our team of scientists are here to help you characterize your drug's efficacy profile quickly and comprehensively.
Validated efficacy models ready for testing your molecule
Access lead optimization or custom efficacy models to help you determine the right profile for your disease indication.
Addiction
- Opioid dependence – precipitated withdrawal
- Nicotine dependence – precipitated withdrawal
- Intravenous self-administration – cue reinstatement
CNS
- Anti-convulsant (PTZ)
- Anti-convulsant (ECS)
- Head twitch response test (5 HT2A antagonism)
- Staircase model
- Tail flick
- Randal Selitto
- Hot Plate
Gastrointestinal
- Ferret Emesis (Anti-emetic)
- Inflammatory Bowel Disease: DSS induced, IL-10 knockout, adoptive T cell transfer
Immunogenicity
- Vaccine immunogenicity testing (subunit, live, attenuated, mRNA, self-amplifying RNA, DNA, dermal patches)
Infectious Disease
- Hepatitis B virus (AAV-HBV, HBV/HDV, HBV mutant)
- Hepatitis (infected human liver)
- Human papillomavirus (HPV) challenge
- Influenza challenge
- Rabies challenge
- Respiratory syncytial virus (RSV) challenge
- C. difficile challenge
- Methicillin-resistant Staphylococcus aureus (MRSA) challenge
- Sepsis (various pathogens)
- Thigh PK/PD (MRSA+ various pathogens)
Metabolic Disease
- Type 1 Diabetes (streptozocin-induced)
- Type 2 Diabetes (ob/ob mouse, Zucker rat)
- Obesity (diet-induced)
- Glucose Challenge (oral, IV, IP glucose admin)
- Dietary/Hypercholesterolemia
- NASH (Non-alcoholic steatohepatitis) - AMLN/GAN induced
- NASH - CCl4 induced liver fibrosis
- Glucose telemetry
Oncology
Respiratory Disease
- Asthma
- Ovalbumin sensitization and challenge (airway and nasal challenge)
- House dust mite chronic model
- COPD
- LPS neutrophil chemotaxis model (inhaled and systemic)
- LPS+ FMLP PK/PD model – Neutrophil Elastase targets
- Acute tobacco smoke model (5, 12 and 17 Day model)
- Human neutrophil elastase lung hemorrhage model –neutrophil Elastase targets
- COPD/Asthma: Bronchoconstriction models for LABA, LAMA and MABAs
- Cystic fibrosis: IL-13 PK/PD goblet cell hyperplasia model
- Antitussive: Cough model
- Interstitial Pulmonary Fibrosis: Bleomycin induced lung fibrosis
- Chlorine induced lung injury (chemical injury)
- Allergic Aspergillus- antifungal
- Pulmonary arterial hypertension: Monocrotaline induced pulmonary hypertension
- Flu: H1N1 influenza lung injury/infection model-viral COPD/asthma exacerbation
- Cystic fibrosis: Pseudomonas aeruginosa lung injury /infection model- Bacterial exacerbation
- S.pneumoniae lung infection/COPD exacerbation
